Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Macrophage migration inhibitory factor enhances Pseudomonas aeruginosa biofilm formation, potentially contributing to cystic fibrosis pathogenesis.
Tynan A, Mawhinney L, Armstrong ME, O'Reilly C, Kennedy S, Caraher E, Jülicher K, O'Dwyer D, Maher L, Schaffer K, Fabre A, McKone EF, Leng L, Bucala R, Bernhagen J, Cooke G, Donnelly SC. Tynan A, et al. Among authors: kennedy s. FASEB J. 2017 Nov;31(11):5102-5110. doi: 10.1096/fj.201700463R. Epub 2017 Aug 2. FASEB J. 2017. PMID: 28768722 Free PMC article.
-Tynan, A., Mawhinney, L., Armstrong, M. E., O'Reilly, C., Kennedy, S., Caraher, E., Julicher, K., O'Dwyer, D., Maher, L., Schaffer, K., Fabre, A., McKone, E. F., Leng, L., Bucala, R., Bernhagen, J., Cooke, G., Donnelly, S. C. Macrophage migration inhibitory …
-Tynan, A., Mawhinney, L., Armstrong, M. E., O'Reilly, C., Kennedy, S., Caraher, E., Julicher, K., O'Dwyer, D., Maher, L., Sch …
Postpartum Pharmacologic Thromboprophylaxis and Venous Thromboembolism in a U.S. Cohort.
Bruno AM, Allshouse AA, Saad A, Subramaniam A, Saade GR, Benson M, Szychowski JM, Jauk V, Kim DJ, Larrea N, Kennedy S, Silver RM, Scharfstein D, Metz TD. Bruno AM, et al. Among authors: kennedy s. Obstet Gynecol. 2025 Jan 16. doi: 10.1097/AOG.0000000000005828. Online ahead of print. Obstet Gynecol. 2025. PMID: 39819867
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Yazici Y, Tambiah JRS, Swearingen CJ, Lopez VA, Kennedy S, Fineman MS, Simsek I, Solomon E, Mcalindon TE. Yazici Y, et al. Among authors: kennedy s. Clin Exp Rheumatol. 2025 Jan 13. doi: 10.55563/clinexprheumatol/gskbin. Online ahead of print. Clin Exp Rheumatol. 2025. PMID: 39808288
Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study.
Yazici Y, Tambiah JRS, Swearingen CJ, Britt J, Kennedy S, Fineman MS, Simsek I, Solomon E, McAlindon TE. Yazici Y, et al. Among authors: kennedy s. Clin Exp Rheumatol. 2025 Jan 13. doi: 10.55563/clinexprheumatol/hjt118. Online ahead of print. Clin Exp Rheumatol. 2025. PMID: 39808286
3,161 results